Alex R. Hobson, Zeshan Qureshi, Phil Banks and Nicholas Curzen
The clinical value of dual antiplatelet therapy with aspirin and clopidogrel to reduce platelet-mediated cardiovascular events is now well established in patients with acute coronary syndromes and those receiving intracoronary stents. In the field of PCI, in particular, a large and expanding body of evidence indicates that periprocedural complication rates can be reduced by loading doses of clopidogrel given at least 6 hours before planned stenting. The superiority of 600 mg loading doses of clopidogrel over 300 mg is now widely accepted.
